Manufacturer of Controlled Substances; Notice of Registration, 45783-45784 [E8-18065]
Download as PDF
<![CDATA[
45783
Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices
mstockstill on PROD1PC66 with NOTICES
Drug
Schedule
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
Nicocodeine (9309) .......................
Nicomorphine (9312) ....................
N-Methyl-3-piperidyl
benzilate
(7484).
Noracymethadol (9633) ................
Norlevorphanol (9634) ..................
Normethadone (9635) ...................
Normorphine (9313) ......................
Norpipanone (9636) ......................
Para-Fluorofentanyl (9812) ...........
Parahexyl (7374) ..........................
Peyote (7415) ...............................
Phenadoxone (9637) ....................
Phenampromide (9638) ................
Phenomorphan (9647) ..................
Phenoperidine (9641) ...................
Pholcodine (9314) .........................
Piritramide (9642) .........................
Proheptazine (9643) .....................
Properidine (9644) ........................
Propiram (9649) ............................
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Racemoramide (9645) ..................
Tetrahydrocannabinols (7370) ......
Thebacon (9315) ..........................
Thiofentanyl (9835) .......................
Tilidine (9750) ...............................
Trimeperidine (9646) ....................
1-Phenylcyclohexylamine (7460) ..
1-Piperidinocyclohexanecarbonitrile (8603).
Alfentanil (9737) ............................
Alphaprodine (9010) .....................
Amobarbital (2125) .......................
Amphetamine (1100) ....................
Anileridine (9020) ..........................
Bezitramide (9800) .......................
Carfentanil (9743) .........................
Codeine (9050) .............................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Dihydrocodeine (9120) .................
Dihydroetorphine (9334) ...............
Diphenoxylate (9170) ....................
Ethylmorphine (9190) ...................
Etorphine Hcl (9059) .....................
Fentanyl (9801) .............................
Glutethimide (2550) ......................
Hydrocodone (9193) .....................
Hydromorphone (9150) .................
Isomethadone (9226) ....................
Levo-alphacetylmethadol (9648) ..
Levomethorphan (9210) ...............
Levorphanol (9220) .......................
Lisdexamfetamine (1205) .............
Meperidine (9230) .........................
Meperidine intermediate-A (9232)
Meperidine intermediate-B (9233)
Meperidine intermediate-C (9234)
Metazocine (9240) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Methamphetamine (1105) .............
Methylphenidate (1724) ................
Metopon (9260) ............................
Moramide intermediate (9802) .....
Morphine (9300) ...........................
Nabilone (7379) ............................
Opium, raw (9600) ........................
Opium extracts (9610) ..................
VerDate Aug<31>2005
16:46 Aug 05, 2008
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 214001
Drug
Schedule
Opium fluid extract (9620) ............
Opium tincture (9630) ...................
Opium, granulated (9640) .............
Oxycodone (9143) ........................
Oxymorphone (9652) ....................
Pentobarbital (2270) .....................
Phenazocine (9715) ......................
Phencyclidine (7471) ....................
Phenmetrazine (1631) ..................
Phenylacetone (8501) ...................
Piminodine (9730) .........................
Powdered opium (9639) ...............
Racemethorphan (9732) ...............
Racemorphan (9733) ....................
Remifentanil (9739) ......................
Secobarbital (2315) ......................
Sufentanil (9740) ..........................
Thebaine (9333) ...........................
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import small
quantities of the listed controlled
substances for the National Institute on
Drug Abuse (NIDA) for research
activities.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Research Triangle Institute to import the
basic classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Research Triangle Institute to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: July 29, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–17966 Filed 8–5–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated March 19, 2008 and
published in the Federal Register on
March 28, 2008, (73 FR 16719), Sigma
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
Aldrich Research Biochemicals, Inc., 4–
3 Strathmore Road, Natick,
Massachusetts 01760–2447, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Cathinone (1235) ..........................
Methcathinone (1237) ..................
Aminorex (1585) ...........................
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4-methylenedioxyamphetamine (7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4-Methylenedioxymethamphetamine (MDMA) (7405).
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) (7470).
1-Benzylpiperazine (BZP) (7493)
Heroin (9200) ...............................
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Nabilone (7379) ............................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Ecgonine (9180) ...........................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Meperidine (9230) ........................
Metazocine (9240) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Carfentanil (9743) .........................
Fentanyl (9801) ............................
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
reference standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Sigma Aldrich Research Biochemicals,
Inc. to manufacture the listed basic
classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Sigma
Aldrich Research Biochemicals, Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
E:\FR\FM\06AUN1.SGM
06AUN1
45784
Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: July 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–18065 Filed 8–5–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 28, 2008,
Chattem Chemicals Inc., 3801 St. Elmo
Avenue, Building 18, Chattanooga,
Tennessee 37409, made application by
renewal to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Schedule
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
mstockstill on PROD1PC66 with NOTICES
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 3, 2008,
Chemic Laboratories, Inc., 480 Neponset
Street, Building 7, Canton,
Massachusetts 02021, made application
by renewal to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of Cocaine (9041), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture
small quantities of the above listed
controlled substance for distribution to
its customers for the purpose of
research.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 6, 2008.
Dated: July 28, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–17955 Filed 8–5–08; 8:45 am]
4-Methoxyamphetamine (7411) ....
Difenoxin (9168) ...........................
Amphetamine (1100) ....................
Methamphetamine (1105) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Meperidine (9230) .........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Noroxymorphone (9668) ...............
Alfentanil (9737) ............................
Sufentanil (9740) ..........................
Fentanyl (9801) .............................
16:46 Aug 05, 2008
Jkt 214001
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 6, 2008.
Dated: July 29, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–17961 Filed 8–5–08; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
VerDate Aug<31>2005
I
I
II
II
II
II
II
II
II
II
II
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 3, 2008,
Cambridge Isotope Lab, 50 Frontage
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) as a bulk manufacturer of
Morphine (9300), a basic class of
controlled substance listed in schedule
II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 6, 2008.
Dated: July 29, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–17962 Filed 8–5–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 28, 2008,
Boehringer Ingelheim Chemicals, Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805, made application by
renewal to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Methadone (9250) ........................
E:\FR\FM\06AUN1.SGM
06AUN1
Schedule
II
II
II
II
]]>Agencies
[Federal Register Volume 73, Number 152 (Wednesday, August 6, 2008)]
[Notices]
[Pages 45783-45784]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-18065]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated March 19, 2008 and published in the Federal
Register on March 28, 2008, (73 FR 16719), Sigma Aldrich Research
Biochemicals, Inc., 4-3 Strathmore Road, Natick, Massachusetts 01760-
2447, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
Aminorex (1585)............................ I
Alpha-ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
Tetrahydrocannabinols (7370)............... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
2,5-Dimethoxyamphetamine (7396)............ I
3,4-Methylenedioxyamphetamine (7400)....... I
N-Hydroxy-3,4-methylenedioxy- amphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphet- amine (MDMA) I
(7405).
1-[1-(2-Thienyl)cyclohexyl]piper- idine I
(TCP) (7470).
1-Benzylpiperazine (BZP) (7493)............ I
Heroin (9200).............................. I
Normorphine (9313)......................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Nabilone (7379)............................ II
1-Phenylcyclohexylamine (7460)............. II
Phencyclidine (7471)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Diprenorphine (9058)....................... II
Ecgonine (9180)............................ II
Levomethorphan (9210)...................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Metazocine (9240).......................... II
Methadone (9250)........................... II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Levo-alphacetylmethadol (9648)............. II
Carfentanil (9743)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture reference standards.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Sigma Aldrich Research Biochemicals, Inc. to manufacture the listed
basic classes of controlled substances is consistent with the public
interest at this time. DEA has investigated Sigma Aldrich Research
Biochemicals, Inc. to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical
[[Page 45784]]
security systems, verification of the company's compliance with state
and local laws, and a review of the company's background and history.
Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR
1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: July 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-18065 Filed 8-5-08; 8:45 am]
BILLING CODE 4410-09-P
